Medtronic

Medtronic

Develops and manufactures medical devices and therapies

About Medtronic

Simplify's Rating
Why Medtronic is rated
A-
Rated A on Competitive Edge
Rated A on Growth Potential
Rated B on Rating Differentiation

Industries

Biotechnology

Healthcare

Company Size

10,001+

Company Stage

IPO

Total Funding

$3.2M

Headquarters

Fridley, Minnesota

Founded

1949

Overview

Medtronic provides medical technology, services, and solutions to improve patient care. The company develops a variety of medical devices, including pacemakers, insulin pumps, surgical tools, and neurostimulation devices, which help diagnose, prevent, and treat chronic diseases. These products are used by hospitals and healthcare professionals around the world. Medtronic stands out from competitors by not only focusing on product development but also offering comprehensive services such as training for healthcare providers and patient management programs. The goal of Medtronic is to enhance patient outcomes and lower healthcare costs through its advanced medical solutions.

đź’µ
Funded Recently
Simplify Jobs

Simplify's Take

What believers are saying

  • Growing chronic disease rates boost demand for Medtronic's therapeutic solutions.
  • AI integration in devices enhances Medtronic's diagnostic and treatment capabilities.
  • Personalized medicine trends align with Medtronic's tailored device offerings.

What critics are saying

  • Increased competition in neurostimulation could impact Medtronic's market share.
  • Stricter EU regulations may delay Medtronic's product launches in Europe.
  • Patent litigation could strain Medtronic's financial resources.

What makes Medtronic unique

  • Medtronic's BrainSense™ Adaptive DBS offers personalized Parkinson's treatment, enhancing patient outcomes.
  • The company leads in minimally invasive surgical tools, meeting rising global demand.
  • Medtronic's comprehensive product and service suite supports healthcare providers worldwide.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$3.2M

Above

Industry Average

Funded Over

3 Rounds

Post IPO Debt funding comparison data is currently unavailable. We're working to provide this information soon!
Post IPO Debt Funding Comparison
Coming Soon

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Employee Assistance Program

Wellness Program

Company News

Surgical Robotics Technology
Feb 13th, 2025
Medtronic Acquires Certain Nano Surface Technology from Nanovis

Medtronic acquires certain nano surface technology from Nanovis.

PR Newswire
Feb 5th, 2025
Medtronic To Announce Financial Results For Its Third Quarter Of Fiscal Year 2025

GALWAY, Ireland, Feb. 5, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results for its third quarter of fiscal year 2025 on Tuesday, February 18, 2025. A news release will be issued at approximately 5:45 a.m. Central Standard Time (CST) and will be available at https://news.medtronic.com. The news release will include summary financial information for the company's third quarter of fiscal year 2025, which ended on Friday, January 24, 2025. Medtronic will host a video webcast at 7:00 a.m

Stock Titan
Jan 21st, 2025
Medtronic appoints Thierry Piéton as Chief Financial Officer

GALWAY, Ireland, Jan. 21, 2025 /PRNewswire/ - Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that Thierry Piéton has been appointed Chief Financial Officer for the company, effective March 3, 2025.

Cardiovascular Business
Jan 17th, 2025
Medtronic heart rhythm technologies on full display at AF Symposium 2025

Medtronic's heart rhythm management portfolio, including its insertable cardiac monitors (ICMs) and pulsed field ablation (PFA) systems, have had a significant footprint at AF Symposium 2025, a three-day conference in Boston focused on advanced atrial fibrillation (AFib) technologies.

MedCity News
Jan 15th, 2025
Is Medtronic On the Cusp of Rewriting Its Own Story in Renal Denervation?

Recall that Medtronic acquired the renal denervation technology from Mountain View, California-based Ardian back in 2010 for $800 million plus milestone payments.

Recently Posted Jobs

Sign up to get curated job recommendations

Medtronic is Hiring for 0 Jobs on Simplify!

Find jobs on Simplify and start your career today

đź’ˇ
We update Medtronic's jobs every 8 hours, so check again soon! Browse all jobs →